Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rory McCrimmon

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Diabetes Care|June 26, 2020
Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in ScotlandThomas M Caparrotta, Luke A K Blackbourn, Stuart J McGurnaghan, et al.
Nature Medicine|May 9, 2022
Heterogeneity in phenotype, disease progression and drug response in type 2 diabetesAnand Thakarakkattil Narayanan Nair, Agata Wesolowska-Andersen, Caroline Brorsson, et al.
Diabetes Care|July 10, 2021
Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational StudyJoseph E O'Reilly, Anita Jeyam, Thomas M Caparrotta, et al.
The Lancet. Diabetes & Endocrinology|December 28, 2020
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of ScotlandStuart J McGurnaghan, Amanda Weir, Jen Bishop, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Diabetes Care|June 26, 2020
Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in ScotlandThomas M Caparrotta, Luke A K Blackbourn, Stuart J McGurnaghan, et al.
Nature Medicine|May 9, 2022
Heterogeneity in phenotype, disease progression and drug response in type 2 diabetesAnand Thakarakkattil Narayanan Nair, Agata Wesolowska-Andersen, Caroline Brorsson, et al.
Diabetes Care|July 10, 2021
Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational StudyJoseph E O'Reilly, Anita Jeyam, Thomas M Caparrotta, et al.
The Lancet. Diabetes & Endocrinology|December 28, 2020
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of ScotlandStuart J McGurnaghan, Amanda Weir, Jen Bishop, et al.
Pageof 2